[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556263":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":28,"interventions":45,"overallOfficials":21,"centralContacts":58,"locations":64,"responsibleParty":81,"collaborators":21,"id":83,"slug":21,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":21,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":21,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":21,"overallStatus":67,"whyStopped":21,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":21},[9,13],{"measure":10,"description":11,"timeFrame":12},"ORR","Objective response rate","12 months",{"measure":14,"description":15,"timeFrame":12},"Safety and tolerability","Safety and tolerability assessed by incidence and severity of adverse events",[17],{"measure":18,"description":19,"timeFrame":20},"PFS","The efficacy end point","24 months",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE",[29,36,39,42],{"label":30,"type":31,"description":21,"interventionNames":32},"SSGJ-707(dose 1)+ carboplatin + paclitaxel","EXPERIMENTAL",[33,34,35],"Drug: SSGJ-707","Drug: carboplatin","Drug: paclitaxel",{"label":37,"type":31,"description":21,"interventionNames":38},"SSGJ-707(dose 2)+ carboplatin + paclitaxel",[33,34,35],{"label":40,"type":31,"description":21,"interventionNames":41},"SSGJ-707(dose 3)+ carboplatin + paclitaxel",[33,34,35],{"label":43,"type":31,"description":21,"interventionNames":44},"SSGJ-707(dose 4)+ paclitaxel",[33,35],[46,51,55],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":21},"DRUG","SSGJ-707","SSGJ-707 is a bispecific antibody against human PD-1 and VEGF",[30,37,40,43],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":21},"carboplatin","chemotherapy",[30,37,40],{"type":47,"name":56,"description":53,"armGroupLabels":57,"otherNames":21},"paclitaxel",[30,37,40,43],[59],{"name":60,"role":61,"phone":62,"phoneExt":21,"email":63},"ZHOU, PhD","CONTACT","13708384529","qizhou9128@163.com",[65],{"facility":66,"status":67,"city":68,"state":21,"zip":21,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Chongqing Cancer Hospital","RECRUITING","Chongqing","China","CN",{"type":72,"coordinates":73},"Point",[74,75],106.55771,29.56026,{"lat":75,"lon":74},[78],{"name":79,"role":61,"phone":80,"phoneExt":21,"email":63},"ZHOU QI, PhD","+86 13708384529",{"type":82,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100556263",false,"NCT06522828","A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients","Inclusion Criteria:\n\n1. Age:18-75 years old\n2. Advanced endometrial cancer and platinum-resistant ovarian cancer\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":93,"type":94},80,"ESTIMATED","INTERVENTIONAL",[97],"PHASE2","This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer.",[100],"Advanced\u002Frecurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer","2024-10-17",{"date":103,"type":104},"2024-10-21","ACTUAL",{"date":106,"type":104},"2024-10-10",{"date":108,"type":94},"2026-08",{"name":5,"class":6},1]